109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
ARID3A 通过激活双表型肝细胞癌中的 TNF-α/NF-κB 信号通路促进肿瘤进展
Authors Li M, Yang T, Huang J, Wu X , Chen J, Li J, Shi B, Zhang J , Xiang B
Received 25 June 2025
Accepted for publication 5 November 2025
Published 19 November 2025 Volume 2025:12 Pages 2553—2564
DOI https://doi.org/10.2147/JHC.S549213
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr David Gerber
Minjun Li,1,2,* Taixin Yang,1,* Juntao Huang,1 Xinyuan Wu,1 Jingyu Chen,1 Jindu Li,1 Binglin Shi,3 Jie Zhang,1 Bangde Xiang1,2
1Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People’s Republic of China; 2Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, Guangxi, People’s Republic of China; 3Department of General Surgery, Fangchenggang First People’s Hospital, Fangchenggang, Guangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Bangde Xiang, Email xiangbangde@gxmu.edu.cn Jie Zhang, Email zhangjie1@gxmu.edu.cn
Objective: Dual-phenotype hepatocellular carcinoma (DPHCC) is a unique subtype of hepatocellular carcinoma (HCC) characterized by strong tumor stemness and invasive capabilities. ARID3A is identified as a potential regulator of tumor stemness in DPHCC by applying transcriptomic analysis. The precise mechanisms of ARID3A on the aggressive behavior of DPHCC remain to be further explored.
Materials and Methods: In vitro functional experiments and in vivo tumorigenesis assays were used to validate the malignant behaviors of ARID3A. RNA sequencing was performed on ARID3A-transfected cells to identify ARID3A-mediated regulatory mechanisms. Finally, the impact of ARID3A–TNF-α/NF-κB axis on HCC malignant behavior was analyzed through in vitro blocking or stimulation experiments.
Results: The expression of ARID3A was upregulated in DPHCC and was associated with poor prognosis among these patients (p = 0.006, HR = 3.77, 95% CI:1.762– 8.069). In vitro and in vivo experiments indicated that ARID3A facilitated stemness features and tumor progression. Findings from RNA-seq suggested that ARID3A enhanced tumor stemness and activated epithelial-mesenchymal transition through the activation of TNF-α-mediated NF-κB signaling. In vitro stimulation of ARID3A-transfected cells lines with recombinant TNF-α protein or inhibition of TNF-α-mediated NF-κB signaling regulated the ARID3A-mediated invasiveness.
Conclusion: Our study reveals that ARID3A acts as an oncogene and promotes aggressive features of stem-like cells in DPHCC via the ARID3A–TNF-α/NF-κB axis. Thus, it may facilitate the development therapeutic strategy for DPHCC.
Keywords: dual-phenotype HCC, ARID3A oncogene, inflammatory signaling
1Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People’s Republic of China; 2Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, Guangxi, People’s Republic of China; 3Department of General Surgery, Fangchenggang First People’s Hospital, Fangchenggang, Guangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Bangde Xiang, Email xiangbangde@gxmu.edu.cn Jie Zhang, Email zhangjie1@gxmu.edu.cn
Objective: Dual-phenotype hepatocellular carcinoma (DPHCC) is a unique subtype of hepatocellular carcinoma (HCC) characterized by strong tumor stemness and invasive capabilities. ARID3A is identified as a potential regulator of tumor stemness in DPHCC by applying transcriptomic analysis. The precise mechanisms of ARID3A on the aggressive behavior of DPHCC remain to be further explored.
Materials and Methods: In vitro functional experiments and in vivo tumorigenesis assays were used to validate the malignant behaviors of ARID3A. RNA sequencing was performed on ARID3A-transfected cells to identify ARID3A-mediated regulatory mechanisms. Finally, the impact of ARID3A–TNF-α/NF-κB axis on HCC malignant behavior was analyzed through in vitro blocking or stimulation experiments.
Results: The expression of ARID3A was upregulated in DPHCC and was associated with poor prognosis among these patients (p = 0.006, HR = 3.77, 95% CI:1.762– 8.069). In vitro and in vivo experiments indicated that ARID3A facilitated stemness features and tumor progression. Findings from RNA-seq suggested that ARID3A enhanced tumor stemness and activated epithelial-mesenchymal transition through the activation of TNF-α-mediated NF-κB signaling. In vitro stimulation of ARID3A-transfected cells lines with recombinant TNF-α protein or inhibition of TNF-α-mediated NF-κB signaling regulated the ARID3A-mediated invasiveness.
Conclusion: Our study reveals that ARID3A acts as an oncogene and promotes aggressive features of stem-like cells in DPHCC via the ARID3A–TNF-α/NF-κB axis. Thus, it may facilitate the development therapeutic strategy for DPHCC.
Keywords: dual-phenotype HCC, ARID3A oncogene, inflammatory signaling